Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

Video

In Partnership With:

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses the mechanism of action of ibrutinib (Imbruvica) combined with rituximab and bendamustine as treatment for chronic lymphocytic leukemia (CLL).

Bendamustine has long been determined by researchers as an impactful treatment in CLL, Chanan-Khan explains. Rituximab also has known benefits in patients as an immunotherapy, while ibrutinib is able to directly target the cancer cells. This triplet provides different ways to target these cells and provide clinically meaningful benefits to patients, he adds.

However, it is too early to determine if this triplet has curative potential, Chanan-Khan says.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD